These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37907515)

  • 1. SDC1 and ITGA2 as novel prognostic biomarkers for PDAC related to IPMN.
    Zhang CL; Shen Q; Liu FD; Yang F; Gao MQ; Jiang XC; Li Y; Zhang XY; En GE; Pan X; Pang B
    Sci Rep; 2023 Oct; 13(1):18727. PubMed ID: 37907515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
    Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
    Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
    Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
    Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioinformatic Analysis Suggests That Three Hub Genes May Be a Vital Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma.
    Chang X; Yang MF; Fan W; Wang LS; Yao J; Li ZS; Li DF
    J Comput Biol; 2020 Nov; 27(11):1595-1609. PubMed ID: 32216644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of hub genes and regulators associated with pancreatic ductal adenocarcinoma based on integrated gene expression profile analysis.
    Shang M; Zhang L; Chen X; Zheng S
    Discov Med; 2019 Sep; 28(153):159-172. PubMed ID: 31926587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Circulating miRNA Signatures for Early Detection of Pancreatic Neoplasia.
    Vila-Navarro E; Duran-Sanchon S; Vila-Casadesús M; Moreira L; Ginès À; Cuatrecasas M; Lozano JJ; Bujanda L; Castells A; Gironella M
    Clin Transl Gastroenterol; 2019 Apr; 10(4):e00029. PubMed ID: 31009404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma.
    Ideno N; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Tamura K; Aso T; Aishima S; Miyasaka Y; Ohuchida K; Ueda J; Takahata S; Oda Y; Mizumoto K; Tanaka M
    Pancreas; 2015 Mar; 44(2):311-20. PubMed ID: 25479586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial-to-mesenchymal transition (EMT) in intraductal papillary mucinous neoplasm (IPMN) is associated with high tumor grade and adverse outcomes.
    Lahat G; Lubezky N; Loewenstein S; Nizri E; Gan S; Pasmanik-Chor M; Hayman L; Barazowsky E; Ben-Haim M; Klausner JM
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S750-7. PubMed ID: 25069861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Analysis of Molecular Biologic Characteristics of Pancreatic Ductal Adenocarcinoma Concomitant with Intraductal Papillary Mucinous Neoplasm.
    Tsujimae M; Masuda A; Ikegawa T; Tanaka T; Inoue J; Toyama H; Sofue K; Uemura H; Kohashi S; Inomata N; Nagao K; Masuda S; Abe S; Gonda M; Yamakawa K; Ashina S; Yamada Y; Tanaka S; Nakano R; Sakai A; Kobayashi T; Shiomi H; Kanzawa M; Itoh T; Fukumoto T; Ueda Y; Kodama Y
    Ann Surg Oncol; 2022 Aug; 29(8):4924-4934. PubMed ID: 35606470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of para-aortic lymph node status in resected pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous neoplasm - Time to consider a reclassification?
    Linder S; Holmberg M; Engstrand J; Ghorbani P; Sparrelid E
    Surg Oncol; 2022 May; 41():101735. PubMed ID: 35287096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ITGA2, LAMB3, and LAMC2 may be the potential therapeutic targets in pancreatic ductal adenocarcinoma: an integrated bioinformatics analysis.
    Islam S; Kitagawa T; Baron B; Abiko Y; Chiba I; Kuramitsu Y
    Sci Rep; 2021 May; 11(1):10563. PubMed ID: 34007003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional reprogramming of peripheral blood monocytes by soluble mediators in patients with pancreatic cancer and intraductal papillary mucinous neoplasms.
    Eckhoff AM; Brown MC; Landa K; Naqvi I; Holl EK; Boczkowski D; Fletcher A; Rhodin KE; Giang MH; Sullenger B; Beasley GM; Allen PJ; Nair SK
    Front Immunol; 2023; 14():1116034. PubMed ID: 37575220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival.
    Gavazzi F; Capretti G; Giordano L; Ridolfi C; Spaggiari P; Sollai M; Carrara S; Nappo G; Bozzarelli S; Zerbi A
    Dig Liver Dis; 2022 Jun; 54(6):826-833. PubMed ID: 34219044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
    Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
    Front Immunol; 2021; 12():648917. PubMed ID: 33777046
    [No Abstract]   [Full Text] [Related]  

  • 15. Knockdown of FOXO3a induces epithelial-mesenchymal transition and promotes metastasis of pancreatic ductal adenocarcinoma by activation of the β-catenin/TCF4 pathway through SPRY2.
    Li J; Yang R; Dong Y; Chen M; Wang Y; Wang G
    J Exp Clin Cancer Res; 2019 Jan; 38(1):38. PubMed ID: 30691517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of differentially expressed genes in pancreatic ductal adenocarcinoma and normal pancreatic tissues based on microarray datasets.
    Liu L; Wang S; Cen C; Peng S; Chen Y; Li X; Diao N; Li Q; Ma L; Han P
    Mol Med Rep; 2019 Aug; 20(2):1901-1914. PubMed ID: 31257501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel genes associated with a poor prognosis in pancreatic ductal adenocarcinoma via a bioinformatics analysis.
    Zhou J; Hui X; Mao Y; Fan L
    Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31311829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Key Prognostic Biomarker and Its Correlation with Immune Infiltrates in Pancreatic Ductal Adenocarcinoma.
    Luan H; Zhang C; Zhang T; He Y; Su Y; Zhou L
    Dis Markers; 2020; 2020():8825997. PubMed ID: 32934754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic ductal adenocarcinomas associated with intraductal papillary mucinous neoplasms (IPMNs) versus pseudo-IPMNs: relative frequency, clinicopathologic characteristics and differential diagnosis.
    Muraki T; Jang KT; Reid MD; Pehlivanoglu B; Memis B; Basturk O; Mittal P; Kooby D; Maithel SK; Sarmiento JM; Christians K; Tsai S; Evans D; Adsay V
    Mod Pathol; 2022 Jan; 35(1):96-105. PubMed ID: 34518632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of a prognostic prediction system for pancreatic ductal adenocarcinoma to investigate the key prognostic genes.
    Zheng B; Peng J; Mollayup A; Bakri A; Guo L; Zheng J; Xu H
    Mol Med Rep; 2018 Jan; 17(1):216-224. PubMed ID: 29115420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.